Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozuleristide - Blaze Bioscience

Next Previous
Drug Profile

Tozuleristide - Blaze Bioscience

Alternative Names: BLZ-100; Chlorotoxin conjugated to indocyanine green dye - Blaze Bioscience; Chlorotoxin-indocyanine-green-conjugate; CyTP-007; Tumor Paint BLZ-100; Tumour paint

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blaze Bioscience
  • Developer Blaze Bioscience; Seattle Children's Hospital
  • Class Biological toxins; Drug conjugates; Imaging agents; Indoles; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III CNS cancer
  • Phase I/II Mouth neoplasm; Squamous cell cancer
  • Preclinical Lung cancer
  • No development reported Breast cancer; Glioma; Head and neck cancer; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 21 Apr 2025 Blaze Bioscience completes an expanded access programme in patients with life-threatening diseases or conditions who have exhausted approved treatment options and are unable to participate in a clinical trial (NCT04343274)
  • 06 Mar 2025 Blaze Biosciences and Cedars-Sinai Medical Centre completes a phase-II trial in CNS cancer (Diagnosis, In adults, In the elderly) in USA (IV) (NCT04743310)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Diagnosis) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top